AU2001257129A1 - Novel pharmacotherapeutic process and composition for central nervous system disorders - Google Patents

Novel pharmacotherapeutic process and composition for central nervous system disorders

Info

Publication number
AU2001257129A1
AU2001257129A1 AU2001257129A AU5712901A AU2001257129A1 AU 2001257129 A1 AU2001257129 A1 AU 2001257129A1 AU 2001257129 A AU2001257129 A AU 2001257129A AU 5712901 A AU5712901 A AU 5712901A AU 2001257129 A1 AU2001257129 A1 AU 2001257129A1
Authority
AU
Australia
Prior art keywords
composition
nervous system
central nervous
system disorders
pharmacotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257129A
Inventor
Michael J. Kubek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of AU2001257129A1 publication Critical patent/AU2001257129A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
AU2001257129A 2000-04-21 2001-04-20 Novel pharmacotherapeutic process and composition for central nervous system disorders Abandoned AU2001257129A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19897000P 2000-04-21 2000-04-21
US60198970 2000-04-21
PCT/US2001/012850 WO2001080830A2 (en) 2000-04-21 2001-04-20 Pharmacotherapeutic process and composition for central nervous system disorders

Publications (1)

Publication Number Publication Date
AU2001257129A1 true AU2001257129A1 (en) 2001-11-07

Family

ID=22735659

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257129A Abandoned AU2001257129A1 (en) 2000-04-21 2001-04-20 Novel pharmacotherapeutic process and composition for central nervous system disorders

Country Status (4)

Country Link
US (1) US7229635B2 (en)
AU (1) AU2001257129A1 (en)
CA (1) CA2406846C (en)
WO (1) WO2001080830A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008464A1 (en) * 1996-08-29 1998-03-05 Advanced Research & Technology Institute Novel pharmacotherapeutic process and composition for central nervous system disorders
AU2003222033A1 (en) 2002-03-20 2003-10-08 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
MX2007004676A (en) 2004-10-27 2007-11-14 Univ Denver Adrenocorticotropic hormone analogs and related methods.
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
WO2009033687A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Spantide ii and bfgf (119-126) for therapeutic applications
KR20100056509A (en) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 Use of a peptide as a therapeutic agent
US11660270B2 (en) * 2017-07-20 2023-05-30 Indiana University Research And Technology Corporation Nanoparticle compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941127A (en) * 1974-10-03 1976-03-02 Froning Edward C Apparatus and method for stereotaxic lateral extradural disc puncture
JP2551756B2 (en) * 1985-05-07 1996-11-06 武田薬品工業株式会社 Polyoxycarboxylic acid ester and method for producing the same
JP2526589B2 (en) 1986-08-08 1996-08-21 武田薬品工業株式会社 Peptide-containing microcapsule and method for producing the same
US5487739A (en) * 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5171812A (en) * 1990-01-19 1992-12-15 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
DE69133136T2 (en) * 1990-05-16 2003-06-18 Southern Res Inst Birmingham MICROCAPSULES WITH CONTROLLED RELEASE AND THEIR USE FOR STIMULATING NERVOUS FIBER GROWTH
FR2742989B1 (en) 1995-12-29 1998-01-23 Adir BIOADHESIVE PHARMACEUTICAL COMPOSITION FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS
WO1998008464A1 (en) * 1996-08-29 1998-03-05 Advanced Research & Technology Institute Novel pharmacotherapeutic process and composition for central nervous system disorders

Also Published As

Publication number Publication date
CA2406846C (en) 2008-11-18
WO2001080830A2 (en) 2001-11-01
WO2001080830A3 (en) 2002-04-04
US20030211966A1 (en) 2003-11-13
US7229635B2 (en) 2007-06-12
CA2406846A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2862200A (en) Compositions, kits, apparatus, and methods for inhibiting cerebral neurovasculardisorders and muscular headaches
AU2001285159A1 (en) Methods for treating endocrine disorders
AU2001240546A1 (en) Method for the preparation of hydrogenated hydrocarbons
AU7085100A (en) Method for treating otic disorders
AU3514099A (en) Methods for microsphere production
AU6198700A (en) Process for producing phenyl-alkanes compositions produced therefrom, and uses thereof
GB0023659D0 (en) Dispersion composition and method for producing the same
AU2002211688A1 (en) Method for treating ischemic events affecting the central nervous system
AU2002212226A1 (en) Use of indole derivatives for treating illnesses of the central nervous system
IL157881A0 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU8562898A (en) Thienopyridine derivatives, intermediates thereof, and process for producing theboth
AU7060100A (en) Hydrogenation process
AU3194200A (en) Process for producing l-lysine
AU2001257129A1 (en) Novel pharmacotherapeutic process and composition for central nervous system disorders
AU4239597A (en) Novel pharmacotherapeutic process and composition for central nervous system disorders
AU2001248825A1 (en) Process for producing microsphere
AU5054299A (en) Amine production
AU2002218440A1 (en) New process
AU8627798A (en) Biocatalytic process for the preparation of 3-0-acyl-flavonoids
AUPQ583100A0 (en) Fastening apparatus and methods for their production and use
AU2002242348A1 (en) Process for obtaining 3'-epilutein
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
AU2001227098A1 (en) Support for fixing nucleotide and process for producing the same
AU3149100A (en) Process for producing tapered block copolymers
AU3060500A (en) 1,4-diazacycloheptane compounds, process for their preparation, and their use asmedicaments